Watch for downward pressure on APGE shares as the market interprets these sales as negative signaling, especially given the proximity to a large dilutive offering. The fact that both the CFO and CMO sold, not just one-off participants, increases the perceived credibility of the bearish signal. Consider hedging long positions or monitoring for further insider exits.
APGE drugs
APGE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $84.24entry
- T+1 · 8mo ago +0.12%α +0.04% · $84.34
- T+5 · 7mo ago +2.71%α −1.06% · $86.52
- T+20 · 7mo ago −2.62%α −12.35% · $82.03
- T+60 · 5mo ago +57.42%α +44.04% · $132.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Apogee Therapeutics insiders, the CFO and CMO, sold a combined $303K in stock within a week of a $350M public offering, suggesting potential insider concern ahead of material dilution. The sales represent informed selling by senior executives just after the company priced its secondary offering above market.
Key Financial Metrics
Key Facts
- CFO Jane Henderson sold $76,014 in shares (900 shares at $84.46) on April 1, 2026
- CMO Carl Dambkowski sold $227,468 in shares (2,698 shares at $84.31) on April 1, 2026
- Total open-market insider sales: $303,482
- Sales occurred 7 days after final pricing of a $350M secondary offering (5M shares at $70.00)
- Offering priced below market ($70 vs $73 closing price on March 24), but insiders sold near post-offering price of $84
- Insiders sold after underwriting agreement was signed and offering terms finalized
Financial Impact
$303K in insider selling, representing 0.005% of $5.9B market cap, modest in size but highly significant due to timing and participants
Risk Factors
- Insiders may have sold for personal liquidity needs unrelated to company outlook
- Stock price had run up post-offering, prompting routine profit-taking
- Exercise-and-sell transaction (by Dambkowski) could be part of a pre-arranged 10b5-1 plan
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APGE-1775260875343 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers